Search

Your search keyword '"Carrera, Carlo Giovanni"' showing total 4 results
Start Over Author "Carrera, Carlo Giovanni" Publisher mdpi ag
4 results on '"Carrera, Carlo Giovanni"'

1. Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS)

Author

Gargiulo, Luigi, primary, Ibba, Luciano, additional, Malagoli, Piergiorgio, additional, Amoruso, Fabrizio, additional, Argenziano, Giuseppe, additional, Balato, Anna, additional, Bardazzi, Federico, additional, Burlando, Martina, additional, Carrera, Carlo Giovanni, additional, Damiani, Giovanni, additional, Dapavo, Paolo, additional, Dini, Valentina, additional, Franchi, Chiara, additional, Gaiani, Francesca Maria, additional, Girolomoni, Giampiero, additional, Guarneri, Claudio, additional, Lasagni, Claudia, additional, Loconsole, Francesco, additional, Marzano, Angelo Valerio, additional, Maurelli, Martina, additional, Megna, Matteo, additional, Orsini, Diego, additional, Sampogna, Francesca, additional, Travaglini, Massimo, additional, Valenti, Mario, additional, Costanzo, Antonio, additional, and Narcisi, Alessandra, additional

Published
2024
Full Text
View/download PDF

2. Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement

Author

Fargnoli, Maria Concetta, primary, Bardazzi, Federico, additional, Bianchi, Luca, additional, Dapavo, Paolo, additional, Fabbrocini, Gabriella, additional, Gisondi, Paolo, additional, Micali, Giuseppe, additional, Offidani, Anna Maria, additional, Pellacani, Giovanni, additional, Skroza, Nevena, additional, Angileri, Rosa Giuseppa, additional, Burlando, Martina, additional, Campanati, Anna, additional, Carrera, Carlo Giovanni, additional, Chiricozzi, Andrea, additional, Conti, Andrea, additional, Simone, Clara De, additional, Di Lernia, Vito, additional, Errichetti, Enzo, additional, Galluzzo, Marco, additional, Guarneri, Claudio, additional, Lasagni, Claudia, additional, Lembo, Serena, additional, Loconsole, Francesco, additional, Megna, Matteo, additional, Musumeci, Maria Letizia, additional, Prignano, Francesca, additional, Richetta, Antonio Giovanni, additional, Trovato, Emanuele, additional, Venturini, Marina, additional, Peris, Ketty, additional, and Pinton, Piergiacomo Calzavara, additional

Published
2023
Full Text
View/download PDF

3. Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study

Author

Avallone, Gianluca, primary, Maronese, Carlo Alberto, additional, Murgia, Giulia, additional, Carrera, Carlo Giovanni, additional, Mastorino, Luca, additional, Roccuzzo, Gabriele, additional, Dapavo, Paolo, additional, Alberti-Violetti, Silvia, additional, Quaglino, Pietro, additional, Ribero, Simone, additional, and Marzano, Angelo Valerio, additional

Published
2023
Full Text
View/download PDF

4. Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement

Author

Maria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, Paolo Dapavo, Gabriella Fabbrocini, Paolo Gisondi, Giuseppe Micali, Anna Maria Offidani, Giovanni Pellacani, Nevena Skroza, Rosa Giuseppa Angileri, Martina Burlando, Anna Campanati, Carlo Giovanni Carrera, Andrea Chiricozzi, Andrea Conti, Clara De Simone, Vito Di Lernia, Enzo Errichetti, Marco Galluzzo, Claudio Guarneri, Claudia Lasagni, Serena Lembo, Francesco Loconsole, Matteo Megna, Maria Letizia Musumeci, Francesca Prignano, Antonio Giovanni Richetta, Emanuele Trovato, Marina Venturini, Ketty Peris, Piergiacomo Calzavara Pinton, Fargnoli, Maria Concetta, Bardazzi, Federico, Bianchi, Luca, Dapavo, Paolo, Fabbrocini, Gabriella, Gisondi, Paolo, Micali, Giuseppe, Offidani, Anna Maria, Pellacani, Giovanni, Skroza, Nevena, Angileri, Rosa Giuseppa, Burlando, Martina, Campanati, Anna, Carrera, Carlo Giovanni, Chiricozzi, Andrea, Conti, Andrea, Simone, Clara De, Di Lernia, Vito, Errichetti, Enzo, Galluzzo, Marco, Guarneri, Claudio, Lasagni, Claudia, Lembo, Serena, Loconsole, Francesco, Megna, Matteo, Musumeci, Maria Letizia, Prignano, Francesca, Richetta, Antonio Giovanni, Trovato, Emanuele, Venturini, Marina, Peris, Ketty, and Pinton, Piergiacomo Calzavara

Subjects
brodalumab, Delphi, consensus, statement, psoriasis, consensu, brodalumab therapy psoriasis, General Medicine
Abstract

Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against interleukin-17RA that has been approved for the treatment of moderate-to-severe psoriasis in Europe. We developed a Delphi consensus document focused on brodalumab for the treatment of moderate-to-severe psoriasis. Based on published literature and their clinical experience a steering committee drafted 17 statements covering 7 domains specific to the treatment of moderate-to-severe psoriasis with brodalumab. A panel of 32 Italian dermatologists indicated their level of agreement using a 5-point Likert scale (from 1 = “strongly disagree” to 5 = “strongly agree”) using an online modified Delphi method. After the first round of voting (32 participants), positive consensus was reached for 15/17 (88.2%) of the proposed statements. Following a face-to-face virtual meeting, the steering committee decided that 5 statements would form “main principles” and 10 statements formed the final list. After a second round of voting, consensus was reached in 4/5 (80%) of the main principles and 8/10 (80%) for consensus statements. The final list of 5 main principles and 10 consensus statements identify key indications specific to the use of brodalumab in the treatment of moderate-to-severe psoriasis in Italy. These statements aid dermatologists in the management of patients with moderate-to-severe psoriasis.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results